BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bizama C, García P, Espinoza JA, Weber H, Leal P, Nervi B, Roa JC. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev. 2015;41:222-234. [PMID: 25639632 DOI: 10.1016/j.ctrv.2015.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP, Chiplunkar SV. IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 2016;139:869-81. [PMID: 27062572 DOI: 10.1002/ijc.30134] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 11.8] [Reference Citation Analysis]
2 Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, Radhakrishnan A, Chavan S, Raja R, Pinto SM, Patil AH, Barbhuiya MA, Kumar P, Guerrero-Preston R, Navani S, Tiwari PK, Kumar RV, Prasad TSK, Roa JC, Pandey A, Sidransky D, Gowda H, Izumchenko E, Chatterjee A. PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). J Cell Commun Signal 2019;13:163-77. [PMID: 30666556 DOI: 10.1007/s12079-018-00503-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang N, Xiang X, Chen K, Liu P, Zhu A. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie 2018;146:56-67. [PMID: 29155108 DOI: 10.1016/j.biochi.2017.10.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
4 Baichan P, Naicker P, Devar JWS, Smith M, Candy GP, Nweke E. Targeting gallbladder cancer: a pathway based perspective. Mol Biol Rep 2020;47:2361-9. [PMID: 32020429 DOI: 10.1007/s11033-020-05269-x] [Reference Citation Analysis]
5 Zhao S, Miao Y, Wang R, Guo H, Jin F, Guo X, Luo T. Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis. Onco Targets Ther 2016;9:6695-700. [PMID: 27822072 DOI: 10.2147/OTT.S110926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Ni G, Wang T, Yang L, Wang Y, Liu X, Wei MQ. Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. Hum Vaccin Immunother 2016;12:599-606. [PMID: 26367244 DOI: 10.1080/21645515.2015.1089008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Chen M, Huang M, Chen W, Jiang X, Su W, Wang X, Tang N, She F, Chen Y. Smac mimetic promotes TNF-α to induce apoptosis of gallbladder carcinoma cells. Cell Signal 2020;72:109654. [PMID: 32334028 DOI: 10.1016/j.cellsig.2020.109654] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chandra V, Kim JJ, Mittal B, Rai R. MicroRNA aberrations: An emerging field for gallbladder cancer management. World J Gastroenterol 2016;22:1787-99. [PMID: 26855538 DOI: 10.3748/wjg.v22.i5.1787] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
9 Lombardi P, Marino D, Fenocchio E, Chilà G, Aglietta M, Leone F. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opin Emerg Drugs 2018;23:63-75. [PMID: 29468924 DOI: 10.1080/14728214.2018.1444749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
10 Varamo C, Peraldo-Neia C, Ostano P, Basiricò M, Raggi C, Bernabei P, Venesio T, Berrino E, Aglietta M, Leone F, Cavalloni G. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers (Basel) 2019;11:E519. [PMID: 30979003 DOI: 10.3390/cancers11040519] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
11 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
12 Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR. Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer 2018;18:665. [PMID: 29914418 DOI: 10.1186/s12885-018-4575-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
13 Liu Y, Bi T, Yuan F, Gao X, Jia G, Tian Z. S-adenosylmethionine induces apoptosis and cycle arrest of gallbladder carcinoma cells by suppression of JAK2/STAT3 pathways. Naunyn Schmiedebergs Arch Pharmacol 2020;393:2507-15. [PMID: 32219484 DOI: 10.1007/s00210-020-01858-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. Oncotarget 2017;8:26169-84. [PMID: 28412732 DOI: 10.18632/oncotarget.15410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
15 Liu S, Li F, Pan L, Yang Z, Shu Y, Lv W, Dong P, Gong W. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo. Cancer Sci 2019;110:2493-506. [PMID: 31215139 DOI: 10.1111/cas.14102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
16 Sharma P, Caldwell TS, Rivera MN, Gullapalli RR. Cadmium exposure activates Akt/ERK Signaling and pro-inflammatory COX-2 expression in human gallbladder epithelial cells via a ROS dependent mechanism. Toxicol In Vitro 2020;67:104912. [PMID: 32512147 DOI: 10.1016/j.tiv.2020.104912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mohri D, Ijichi H, Miyabayashi K, Takahashi R, Kudo Y, Sasaki T, Asaoka Y, Tanaka Y, Ikenoue T, Tateishi K, Tada M, Isayama H, Koike K. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. J Gastroenterol 2016;51:711-21. [PMID: 26614007 DOI: 10.1007/s00535-015-1145-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Dubé-Delarosbil C, St-Pierre Y. The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci 2018;75:1215-26. [PMID: 29119229 DOI: 10.1007/s00018-017-2708-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground? European Journal of Cancer 2017;81:161-73. [DOI: 10.1016/j.ejca.2017.05.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
20 Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang XA, Mu J, Hu YP, Jiang L, Dong P, Gong W, Liu Y. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci Rep 2016;6:26351. [PMID: 27283076 DOI: 10.1038/srep26351] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
21 Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, Brunauer G, Steger G, Zielinski CC, Prager GW. Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. J Gastrointest Oncol. 2016;7:588-594. [PMID: 27563449 DOI: 10.21037/jgo.2016.05.01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
22 Salman T, Argon A, Kebat T, Vardar E, Erkan N, Alacacıoğlu A. The prognostic significance of survivin expression in gallbladder carcinoma. APMIS 2016;124:633-8. [DOI: 10.1111/apm.12551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Xie Y, Lin JZ, Wang AQ, Xu WY, Long JY, Luo YF, Shi J, Liang ZY, Sang XT, Zhao HT. Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. World J Gastroenterol 2017;23:5787-97. [PMID: 28883705 DOI: 10.3748/wjg.v23.i31.5787] [Reference Citation Analysis]
24 Ramos E, Lluis N, Llado L, Torras J, Busquets J, Rafecas A, Serrano T, Mils K, Leiva D, Fabregat J. Prognostic value and risk stratification of residual disease in patients with incidental gallbladder cancer. World J Surg Oncol 2020;18:18. [PMID: 31980034 DOI: 10.1186/s12957-020-1794-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Deng XT, Tang SM, Wu PY, Li QP, Ge XX, Xu BM, Wang HS, Miao L. SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J Cell Mol Med 2019;23:7961-73. [PMID: 30903649 DOI: 10.1111/jcmm.14230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Bo X, Wang J, Wang C, Nan L, Gao Z, Xin Y, Li M, Shen S, Liu H, Ni X, Suo T, Zhang D, Lu P, Wang Y, Liu H. High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer. Cancer Sci 2020;111:817-25. [PMID: 31925976 DOI: 10.1111/cas.14302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Weber H, Leal P, Stein S, Kunkel H, García P, Bizama C, Espinoza JA, Riquelme I, Nervi B, Araya JC, Grez M, Roa JC. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice. Oncotarget 2015;6:31877-88. [PMID: 26397134 DOI: 10.18632/oncotarget.5047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
28 Yu J, Shi L, Lin W, Lu B, Zhao Y. UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer. Biochem Pharmacol 2020;172:113745. [PMID: 31811866 DOI: 10.1016/j.bcp.2019.113745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
29 Zhang L, Miao R, Zhang X, Chen W, Zhou Y, Wang R, Zhang R, Pang Q, Xu X, Liu C. Exploring the diagnosis markers for gallbladder cancer based on clinical data. Front Med. 2015;9:350-355. [PMID: 26177708 DOI: 10.1007/s11684-015-0402-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jaruvongvanich V, Yang JD, Peeraphatdit T, Roberts LR. The incidence rates and survival of gallbladder cancer in the USA. European Journal of Cancer Prevention 2019;28:1-9. [DOI: 10.1097/cej.0000000000000402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]